Innoviva (INVA) Stock Forecast, Price Target & Predictions
INVA Stock Forecast
Innoviva stock forecast is as follows: an average price target of $13.00 (represents a -35.32% downside from INVA’s last price of $20.10) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
INVA Price Target
The average price target for Innoviva (INVA) is $13.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $13.00. This represents a potential -35.32% downside from INVA's last price of $20.10.
INVA Analyst Ratings
According to 2 Wall Street analysts, Innoviva's rating consensus is 'Buy'. The analyst rating breakdown for INVA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
Innoviva Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2022 | - | Morgan Stanley | $13.00 | $14.72 | -11.68% | -35.32% |
| Jul 15, 2022 | - | Morgan Stanley | $12.00 | $14.37 | -16.49% | -40.30% |
The latest Innoviva stock forecast, released on Aug 08, 2022 by Morgan Stanley company, set a price target of $13.00, which represents a -11.68% decrease from the stock price at the time of the forecast ($14.72), and a -35.32% decrease from INVA last price ($20.10).
Innoviva Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $20.10 | $20.10 | $20.10 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Innoviva stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Innoviva's last price of $20.10. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 18, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Aug 08, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
| Jul 15, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
| Feb 23, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
Innoviva's last stock rating was published by Cantor Fitzgerald on Jun 18, 2024. The company Initialise its INVA rating from "null" to "Overweight".
Innoviva Financial Forecast
Innoviva Revenue Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $85.84M | $67.26M | $80.99M | $76.37M | $65.80M | $67.26M | $108.22M | $90.06M | $100.81M | $90.48M | $88.69M | $78.95M | $78.68M | $75.97M | $65.75M | $64.11M | $55.18M | $52.38M | $40.49M | $24.18M | $6.90M | $165.00K | $1.34M |
| Avg Forecast | $88.39M | $86.86M | $80.42M | $86.80M | $76.91M | $74.69M | $68.00M | $75.52M | $75.66M | $67.92M | $62.01M | $58.85M | $62.60M | $214.78M | $86.40M | $111.23M | $75.30M | $71.10M | $68.30M | $60.80M | $71.80M | $61.70M | $68.90M | $54.50M | $102.86M | $72.90M | $60.50M | $6.13M | $683.87K | $1.30M |
| High Forecast | $90.72M | $89.15M | $82.53M | $91.17M | $76.91M | $76.66M | $69.79M | $77.50M | $77.65M | $69.71M | $63.64M | $60.40M | $62.60M | $214.78M | $86.40M | $133.48M | $75.30M | $71.10M | $68.30M | $60.80M | $71.80M | $61.70M | $68.90M | $54.50M | $123.43M | $87.48M | $72.60M | $7.36M | $820.64K | $1.56M |
| Low Forecast | $86.06M | $84.57M | $78.29M | $82.41M | $76.91M | $72.72M | $66.21M | $73.52M | $73.66M | $66.12M | $60.37M | $57.30M | $62.60M | $214.78M | $86.40M | $88.99M | $75.30M | $71.10M | $68.30M | $60.80M | $71.80M | $61.70M | $68.90M | $54.50M | $82.29M | $58.32M | $48.40M | $4.91M | $547.10K | $1.04M |
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 20 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 10 | 7 | 14 | 12 | 18 |
| Surprise % | - | - | - | - | - | - | - | 1.14% | 0.89% | 1.19% | 1.23% | 1.12% | 1.07% | 0.50% | 1.04% | 0.91% | 1.20% | 1.25% | 1.16% | 1.29% | 1.06% | 1.07% | 0.93% | 1.01% | 0.51% | 0.56% | 0.40% | 1.12% | 0.24% | 1.03% |
Innoviva's average Quarter revenue forecast for Mar 24 based on 1 analysts is $68.00M, with a low forecast of $66.21M, and a high forecast of $69.79M. INVA's average Quarter revenue forecast represents a -20.78% decrease compared to the company's last Quarter revenue of $85.84M (Dec 23).
Innoviva EBITDA Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 20 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 10 | 7 | 14 | 12 | 18 |
| EBITDA | - | - | - | - | - | - | - | $44.03M | $100.53M | $19.17M | $51.54M | $28.82M | $30.11M | $86.34M | $77.80M | $122.48M | $77.75M | $45.15M | $104.75M | $89.35M | $66.52M | $58.38M | $56.38M | $50.45M | $40.71M | $33.12M | $21.07M | $5.52M | $-62.66M | $-31.49M |
| Avg Forecast | $70.45M | $69.24M | $64.10M | $69.18M | $61.31M | $59.53M | $42.48M | $60.19M | $60.30M | $54.13M | $38.62M | $18.85M | $49.90M | $171.19M | $35.11M | $88.66M | $60.02M | $56.67M | $54.44M | $48.46M | $57.23M | $49.18M | $54.92M | $43.44M | $54.61M | $43.06M | $30.35M | $4.83M | $-52.02M | $-31.49M |
| High Forecast | $72.31M | $71.06M | $65.78M | $72.67M | $61.31M | $61.10M | $50.97M | $61.78M | $61.89M | $55.56M | $46.34M | $22.62M | $49.90M | $171.19M | $42.13M | $106.39M | $60.02M | $56.67M | $54.44M | $48.46M | $57.23M | $49.18M | $54.92M | $43.44M | $65.53M | $51.67M | $36.42M | $5.80M | $-41.62M | $-25.19M |
| Low Forecast | $68.59M | $67.41M | $62.40M | $65.69M | $61.31M | $57.96M | $33.98M | $58.60M | $58.71M | $52.70M | $30.89M | $15.08M | $49.90M | $171.19M | $28.08M | $70.93M | $60.02M | $56.67M | $54.44M | $48.46M | $57.23M | $49.18M | $54.92M | $43.44M | $43.69M | $34.45M | $24.28M | $3.87M | $-62.42M | $-37.79M |
| Surprise % | - | - | - | - | - | - | - | 0.73% | 1.67% | 0.35% | 1.33% | 1.53% | 0.60% | 0.50% | 2.22% | 1.38% | 1.30% | 0.80% | 1.92% | 1.84% | 1.16% | 1.19% | 1.03% | 1.16% | 0.75% | 0.77% | 0.69% | 1.14% | 1.20% | 1.00% |
1 analysts predict INVA's average Quarter EBITDA for Mar 24 to be $42.48M, with a high of $50.97M and a low of $33.98M. This is -3.54% lower than Innoviva's previous annual EBITDA (Dec 23) of $44.03M.
Innoviva Net Income Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 20 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 10 | 7 | 14 | 12 | 18 |
| Net Income | - | - | - | - | - | - | - | $61.53M | $82.05M | $1.28M | $34.87M | $-68.31M | $265.52M | $21.37M | $37.86M | $88.95M | $75.02M | $41.62M | $76.84M | $65.44M | $45.95M | $39.81M | $37.74M | $33.79M | $19.22M | $4.35M | $-8.66M | $-23.37M | $-69.16M | $-41.33M |
| Avg Forecast | $27.07M | $25.81M | $23.92M | $23.29M | $16.68M | $14.79M | $22.99M | $14.48M | $17.00M | $16.37M | $20.90M | $7.49M | $95.66M | $91.71M | $19.00M | $98.15M | $25.01M | $26.26M | $20.01M | $57.66M | $30.95M | $22.82M | $26.57M | $38.48M | $39.68M | $21.90M | $6.39M | $-9.33M | $-56.21M | $-37.36M |
| High Forecast | $28.00M | $26.69M | $24.74M | $28.09M | $17.25M | $15.30M | $27.59M | $14.97M | $17.58M | $16.93M | $25.08M | $8.99M | $95.66M | $91.71M | $22.80M | $117.78M | $25.01M | $26.26M | $20.01M | $69.19M | $30.95M | $22.82M | $26.57M | $46.18M | $47.62M | $26.28M | $7.66M | $-7.47M | $-44.97M | $-29.89M |
| Low Forecast | $26.14M | $24.92M | $23.10M | $18.50M | $16.11M | $14.29M | $18.39M | $13.98M | $16.41M | $15.81M | $16.72M | $6.00M | $95.66M | $91.71M | $15.20M | $78.52M | $25.01M | $26.26M | $20.01M | $46.13M | $30.95M | $22.82M | $26.57M | $30.79M | $31.75M | $17.52M | $5.11M | $-11.20M | $-67.45M | $-44.83M |
| Surprise % | - | - | - | - | - | - | - | 4.25% | 4.83% | 0.08% | 1.67% | -9.12% | 2.78% | 0.23% | 1.99% | 0.91% | 3.00% | 1.58% | 3.84% | 1.13% | 1.48% | 1.74% | 1.42% | 0.88% | 0.48% | 0.20% | -1.36% | 2.50% | 1.23% | 1.11% |
Innoviva's average Quarter net income forecast for Mar 24 is $22.99M, with a range of $18.39M to $27.59M. INVA's average Quarter net income forecast represents a -62.64% decrease compared to the company's last Quarter net income of $61.53M (Dec 23).
Innoviva SG&A Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 20 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 10 | 7 | 14 | 12 | 18 |
| SG&A | - | - | - | - | - | - | - | $26.32M | $28.64M | $23.54M | $19.73M | $17.39M | $27.81M | $11.78M | $6.49M | $4.23M | $5.47M | $3.25M | $2.60M | $2.56M | $2.33M | $4.96M | $4.35M | $3.02M | $11.69M | $10.79M | $6.25M | $5.44M | $22.83M | $8.31M |
| Avg Forecast | $11.19M | $11.00M | $10.18M | $10.99M | $9.74M | $9.46M | $9.46M | $9.56M | $9.58M | $8.60M | $8.60M | $2.26M | $7.93M | $27.19M | $7.82M | $4.67M | $9.53M | $9.00M | $8.65M | $2.26M | $9.09M | $7.81M | $8.72M | $3.43M | $15.68M | $14.03M | $9.00M | $4.76M | $86.58K | $164.58K |
| High Forecast | $11.48M | $11.29M | $10.45M | $11.54M | $9.74M | $9.70M | $11.35M | $9.81M | $9.83M | $8.82M | $10.32M | $2.71M | $7.93M | $27.19M | $9.38M | $5.60M | $9.53M | $9.00M | $8.65M | $2.71M | $9.09M | $7.81M | $8.72M | $4.12M | $18.81M | $16.84M | $10.80M | $5.71M | $103.89K | $197.50K |
| Low Forecast | $10.89M | $10.71M | $9.91M | $10.43M | $9.74M | $9.21M | $7.57M | $9.31M | $9.33M | $8.37M | $6.88M | $1.80M | $7.93M | $27.19M | $6.26M | $3.73M | $9.53M | $9.00M | $8.65M | $1.81M | $9.09M | $7.81M | $8.72M | $2.75M | $12.54M | $11.23M | $7.20M | $3.81M | $69.26K | $131.66K |
| Surprise % | - | - | - | - | - | - | - | 2.75% | 2.99% | 2.74% | 2.29% | 7.71% | 3.51% | 0.43% | 0.83% | 0.91% | 0.57% | 0.36% | 0.30% | 1.13% | 0.26% | 0.64% | 0.50% | 0.88% | 0.75% | 0.77% | 0.69% | 1.14% | 263.74% | 50.52% |
Innoviva's average Quarter SG&A projection for Mar 24 is $9.46M, based on 1 Wall Street analysts, with a range of $7.57M to $11.35M. The forecast indicates a -64.05% fall compared to INVA last annual SG&A of $26.32M (Dec 23).
Innoviva EPS Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 20 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 10 | 7 | 14 | 12 | 18 |
| EPS | - | - | - | - | - | - | - | $0.72 | $1.26 | $0.02 | $0.51 | $-0.98 | $3.81 | $0.31 | $0.54 | $1.01 | $0.74 | $0.41 | $0.76 | $0.65 | $0.45 | $0.39 | $0.37 | $0.33 | $0.19 | $0.04 | $-0.08 | $-0.20 | $-0.63 | $-0.43 |
| Avg Forecast | $0.43 | $0.41 | $0.38 | $0.37 | $0.27 | $0.23 | $0.17 | $0.23 | $0.27 | $0.26 | $0.23 | $0.23 | $1.53 | $1.47 | $0.44 | $0.29 | $0.40 | $0.42 | $0.32 | $0.36 | $0.49 | $0.36 | $0.42 | $0.36 | $0.71 | $0.35 | $0.14 | $-0.07 | $-0.44 | $-0.38 |
| High Forecast | $0.44 | $0.42 | $0.39 | $0.45 | $0.27 | $0.24 | $0.18 | $0.24 | $0.28 | $0.27 | $0.24 | $0.23 | $1.53 | $1.47 | $0.44 | $0.29 | $0.40 | $0.42 | $0.32 | $0.36 | $0.49 | $0.36 | $0.42 | $0.36 | $0.85 | $0.42 | $0.17 | $-0.06 | $-0.35 | $-0.30 |
| Low Forecast | $0.42 | $0.40 | $0.37 | $0.29 | $0.26 | $0.23 | $0.16 | $0.22 | $0.26 | $0.25 | $0.22 | $0.22 | $1.53 | $1.47 | $0.44 | $0.29 | $0.40 | $0.42 | $0.32 | $0.36 | $0.49 | $0.36 | $0.42 | $0.36 | $0.57 | $0.28 | $0.12 | $-0.08 | $-0.53 | $-0.46 |
| Surprise % | - | - | - | - | - | - | - | 3.13% | 4.67% | 0.08% | 2.22% | -4.36% | 2.49% | 0.21% | 1.23% | 3.48% | 1.85% | 0.98% | 2.38% | 1.81% | 0.91% | 1.07% | 0.87% | 0.92% | 0.27% | 0.12% | -0.55% | 2.86% | 1.43% | 1.13% |
According to 1 Wall Street analysts, Innoviva's projected average Quarter EPS for Mar 24 is $0.17, with a low estimate of $0.16 and a high estimate of $0.18. This represents a -76.39% decrease compared to INVA previous annual EPS of $0.72 (Dec 23).
Innoviva Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ELEV | Elevation Oncology | $0.62 | $9.00 | 1351.61% | Buy |
| XFOR | X4 Pharmaceuticals | $0.28 | $3.67 | 1210.71% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| INZY | Inozyme Pharma | $3.55 | $14.67 | 313.24% | Buy |
| PDSB | PDS Bio | $2.76 | $9.00 | 226.09% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.53 | $7.00 | 176.68% | Buy |
| APLS | Apellis Pharmaceuticals | $28.25 | $74.50 | 163.72% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.85 | $38.80 | 161.28% | Buy |
| TERN | Terns Pharmaceuticals | $6.78 | $14.25 | 110.18% | Buy |
| FOLD | Amicus Therapeutics | $10.37 | $15.25 | 47.06% | Buy |
| HRMY | Harmony Biosciences | $33.84 | $48.86 | 44.39% | Buy |
| DNLI | Denali Therapeutics | $29.63 | $40.00 | 35.00% | Buy |
| INCY | Incyte | $80.48 | $84.56 | 5.07% | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.68 | $5.33 | -6.16% | Buy |
| HOOK | HOOKIPA Pharma | $3.42 | $3.00 | -12.28% | Buy |
| ARGX | argenx SE | $599.35 | $475.14 | -20.72% | Buy |
| INVA | Innoviva | $20.10 | $13.00 | -35.32% | Buy |